SPY338.99-6.79 -1.96%
DIA276.61-6.73 -2.37%
IXIC11,353.69-194.59 -1.69%

CytoSorbents And Aferetica Announce European Union Approval Of The PerLife System And ECOS-300CY PerSorb Cartridge For Combined Perfusion And Purification Of Solid Organs Dedicated To Transplant

  NEW JERSEY and BOLOGNA, Italy, Oct. 14, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO, USA)) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce

· 10/14/2020 07:07

 

NEW JERSEY and BOLOGNA, Italy, Oct. 14, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO, USA))) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce the European Union approval of Aferetica's PerLife™ ex vivo organ perfusion system and CytoSorbents' ECOS-300CY™ sorbent cartridge for the removal of inflammatory mediators during ex vivo organ perfusion.  The integrated system was developed in concert to improve the preservation and quality of solid organs, like the kidneys and liver, following harvest and prior to transplant into a new recipient.  Aferetica and CytoSorbents have worked closely together to ensure mutual compatibility of their technologies and will introduce the PerLife System and PerSorb™ (ECOS-300CY) adsorber dedicated to Aferetica, with a commercial launch in Italy this quarter.